8-K: Elevation Oncology to Be Acquired by Concentra Biosciences in Cash and Contingent Value Rights Deal

Elevation Oncology, an innovative oncology company, has entered into a definitive merger agreement to be acquired by Concentra Biosciences for $0.36 per share in cash plus a non-tradeable contingent value right tied to net cash and future disposition of its HER3 ADC product candidate, EO-1022.

Summary

• Elevation Oncology, Inc. (Nasdaq: ELEV) has entered into an Agreement and Plan of Merger with Concentra Biosciences, LLC, under which Concentra will acquire Elevation Oncology.
• The acquisition price for each outstanding share of common stock is $0.36 in cash, plus one non-tradeable Contingent Value Right (CVR).
• The CVR entitles holders to contingent cash payments equal to 100% of the amount by which Elevation Oncology's Closing Net Cash exceeds $26.4 million, adjusted for certain claims.
• The CVR also includes 80% of the Net Proceeds from any sale, transfer, license, or other disposition of Elevation Oncology's HER3 antibody-drug conjugate (ADC) product candidate, EO-1022, if such disposition occurs within one year following the merger closing and proceeds are received by the fifth anniversary of the closing.
• The Board of Directors of Elevation Oncology unanimously determined that the acquisition is fair to and in the best interests of the Company and its stockholders, approving the Merger Agreement and recommending stockholders accept the Offer.
• A wholly owned subsidiary of Concentra is required to commence a cash tender offer for all outstanding shares of common stock no later than 10 business days after June 8, 2025.
• The tender offer is subject to conditions, including the tender of at least one share more than 50% of outstanding common stock and the Company having Closing Net Cash of no less than $26.4 million.
• The transaction is not subject to a financing condition.
• Elevation Oncology's directors, officers, and certain affiliated stockholders, collectively holding approximately 5.1% of outstanding common stock, have signed tender and support agreements.
• Outstanding in-the-money stock options will be cancelled for a cash amount (Cash Amount minus exercise price) plus one CVR per share, while out-of-the-money options will be cancelled for no consideration.
• Restricted stock units will have accelerated vesting and be cancelled for a cash amount equal to the Cash Amount plus one CVR.
• Warrants to purchase 22,050,000 shares of common stock will entitle holders to receive an amount in cash equal to their Black Scholes Value.
• The merger is expected to close in July 2025.
• Joseph J. Ferra, Jr. was terminated as President and CEO and resigned from the Board, effective June 30, 2025, receiving severance and potential transaction bonuses.
• Tammy Furlong, the CFO, was appointed President and Interim CEO, effective June 30, 2025, and will receive a $600,000 transaction bonus contingent on the merger closing.
• At the 2025 Annual Meeting, stockholders elected Class I directors, ratified CohnReznick LLP as independent auditor, and approved Board discretion to implement a reverse stock split by December 31, 2025.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the very low cash offer price, the highly speculative and non-tradeable nature of the CVR, and the explicit limitations on future development efforts for the key pipeline asset (EO-1022). While the board's unanimous approval and insider support provide some positive signal for deal completion, the terms suggest a distressed sale rather than a strong strategic acquisition, likely resulting in significant shareholder value erosion for existing investors.

Positives

• The acquisition provides immediate cash value of $0.36 per share to Elevation Oncology stockholders.
• The Contingent Value Right (CVR) offers potential additional upside tied to the company's net cash position and future monetization of the EO-1022 asset.
• The Board of Directors unanimously approved the merger, indicating strong internal support for the transaction.
• The transaction is not subject to a financing condition, reducing uncertainty regarding deal completion.
• Key insiders, including directors and officers, holding approximately 5.1% of shares, have committed to tender their shares, signaling confidence in the deal's completion.

Negatives

• The cash component of the offer price ($0.36 per share) is very low, potentially indicating a distressed sale or a valuation primarily based on the company's cash balance.
• The CVR is non-tradeable, limiting liquidity and the ability for holders to realize its value before potential payouts, which are contingent on uncertain future events.
• The CVR payout for EO-1022 is contingent on a disposition within one year and receipt of proceeds within five years, introducing significant time-based risk and uncertainty.
• The 'Commercially Reasonable Efforts' for EO-1022 disposition explicitly excludes new clinical, manufacturing, or enabling work, which could limit the potential value generation for the asset.
• Out-of-the-Money Options (exercise price equal to or greater than $0.36) will be cancelled for no consideration, negatively impacting holders of such options.
• Elevation Oncology is subject to a $1.2 million termination fee if it enters into a superior proposal, or up to $0.5 million in expense reimbursement if net cash falls below the threshold, creating disincentives for alternative transactions or financial underperformance.
• The termination of the CEO without cause and the appointment of an interim CEO, coupled with significant severance and bonus payments, suggests a major leadership transition and potential instability.

Risks

• The possibility that various closing conditions for the merger may not be satisfied or waived, including uncertainties regarding the percentage of Elevation Oncology's stockholders tendering their shares.
• The risk that competing offers for Elevation Oncology may emerge, potentially disrupting the current merger agreement.
• The risk that the transactions may not be completed in a timely manner, or at all, which could adversely affect Elevation Oncology's business and the price of its common stock.
• Significant costs associated with the proposed transactions, which could impact the company's financial position.
• The risk that any stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• The risk that activities related to the CVR Agreement may not result in any value to Elevation Oncology's stockholders, particularly if no disposition of the EO-1022 product candidate occurs or if net cash falls below the specified threshold.
• The non-tradeable nature of the CVR limits liquidity and the ability for holders to realize its value before potential contingent payouts, which are highly speculative.
• The explicit exclusion of new clinical or manufacturing work from 'Commercially Reasonable Efforts' for EO-1022 disposition implies a limited commitment to further develop the asset, potentially reducing its ultimate monetization value.

Future Outlook

The merger is expected to close in July 2025, following the commencement of a tender offer by June 23, 2025. The potential for future payments to stockholders hinges on the company's net cash exceeding $26.4 million at closing and the successful disposition of the EO-1022 product candidate within one year of closing, with proceeds received by the fifth anniversary. The company will use 'Commercially Reasonable Efforts' for EO-1022 disposition, but this explicitly excludes new clinical or manufacturing work. There is no assurance that CVR holders will receive any payments.

Management Comments

• The Elevation Oncology Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Elevation Oncology stockholders and has approved the Merger Agreement and related transactions.

Industry Context

This acquisition reflects a trend in the biotechnology and oncology sectors where smaller, innovative companies with specific product candidates are acquired by larger entities or investment firms, especially when facing financial constraints or seeking to de-risk further development. The inclusion of a Contingent Value Right (CVR) is a common mechanism in biotech M&A, allowing buyers to cap upfront costs while providing sellers with potential upside tied to future asset performance, particularly for early-stage or unproven assets like EO-1022. The focus on a HER3 antibody-drug conjugate (ADC) aligns with the industry's growing interest in targeted therapies for solid tumors.

Comparison to Industry Standards

• The cash offer of $0.36 per share is significantly below typical acquisition premiums for publicly traded biotech companies, suggesting a distressed sale or a valuation primarily driven by the company's cash balance rather than its pipeline.
• The CVR structure, offering 100% of net cash above a threshold and 80% of future disposition proceeds for a specific asset (EO-1022), is a standard approach in biotech M&A for assets with uncertain future value, similar to deals seen with companies like Alder BioPharmaceuticals (acquired by Lundbeck) or Ignyta (acquired by Roche), where CVRs were used to bridge valuation gaps for clinical-stage assets.
• The 'Commercially Reasonable Efforts' clause for EO-1022, explicitly excluding new clinical or manufacturing work, is a critical detail. This suggests that Concentra's primary intent might be to monetize the existing asset data or intellectual property rather than investing in its further development, which is a common strategy for financial buyers or those seeking to divest non-core assets. This contrasts with strategic acquisitions where the buyer intends to integrate and advance the acquired pipeline.
• The termination fee of $1.2 million and expense reimbursement of up to $0.5 million are within typical ranges (often 1-4% of equity value) for deals of this size, designed to compensate the buyer for due diligence and opportunity costs if the deal falls through.

Management Changes

Corporate Governance

Legal Proceedings

• The document highlights the risk that any stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification, and liability.
• The Company is obligated to provide Parent an opportunity to review and comment on all material filings or responses in connection with any proceedings commenced or threatened by stockholders relating to the transaction.
• The Company shall not settle or compromise such proceedings without Parent's consent.

Related Party Transactions

• Tang Capital Partners, LP (Guarantor), an affiliate of Concentra Biosciences, LLC, has delivered a limited guaranty to Elevation Oncology in respect of certain of Concentra and Merger Sub's obligations arising under the Merger Agreement and CVR Agreement.
• Certain of Elevation Oncology's directors and officers and affiliated stockholders (approximately 5.1% of outstanding shares) have entered into tender and support agreements with Concentra and Merger Sub, agreeing to tender their shares in the Offer.

Stakeholder Impact

• **Shareholders**: Will receive a low cash price per share ($0.36) and a non-tradeable CVR, which offers highly speculative and illiquid potential future payments. Holders of out-of-the-money options will receive no consideration.
• **Employees**: The CEO's employment is terminated, and the CFO is appointed interim CEO, indicating significant leadership changes. While specific broader employee impacts are not detailed, such acquisitions often lead to restructuring and potential job uncertainty.
• **Management**: Key executives, including the former CEO and current CFO/interim CEO, are receiving substantial severance and transaction bonuses, incentivizing their cooperation through the transition.
• **Creditors**: The deal includes a condition that Closing Net Cash be no less than $26.4 million, which helps ensure a certain level of liquidity for the company's liabilities at closing.

Next Steps

• Concentra Merger Sub VI, Inc. to commence a cash tender offer by June 23, 2025.
• Elevation Oncology to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• The merger is expected to close in July 2025, following the tender offer.
• Parent and Merger Sub expect to enter into a Contingent Value Rights Agreement with a rights agent at or prior to the Offer Closing Time.
• Concentra Biosciences to use Commercially Reasonable Efforts to seek partnerships or investments for the CVR Product (EO-1022) and enter into disposition agreements during the Disposition Period (one year post-Merger Closing Date).
• Concentra Biosciences to continue CMC Activities for the CVR Product during the Disposition Period.
• Purchaser to use Commercially Reasonable Efforts to settle and resolve Company Outstanding Liabilities within 30 days of the Merger Closing Date.
• The Surviving Corporation will cause Elevation Oncology's securities to be de-listed from Nasdaq and de-registered under the Exchange Act as promptly as practicable following the Effective Time, and in any event no more than ten days after the Merger Closing Date.
• The Board has discretion to implement a reverse stock split (1-for-10 to 1-for-50) prior to December 31, 2025, subject to Board authority to abandon.

Key Dates

Recommendation

Keywords

Elevation Oncology, Concentra Biosciences, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, EO-1022, HER3 ADC, Biotechnology, Oncology, SEC Filing, 8-K, Corporate Governance, Management Change, Reverse Stock Split